Scientific Focus

Gluten Intolerance and Enteric Infection Affects Millions

The Milky Way Life Science team has over 25 years of experience in the medical research of colostrum. It is using this expertise to unlock the full range of colostrum health benefits to address two disease states: Gluten Intolerance and Enteric Infections (intestinal infections) in children.

7% of US Population Suffers from Gluten Intolerence

When it comes Gluten Intolerance, there is no treatment. The only thing for patients to do is follow a strict gluten-free diet. Yet gluten is everywhere and in everything, including toothpaste, spices, lipstick, and vitamins. 32% of food served in restaurants labeled 'gluten free' contain gluten (The American Journal of Gastroenterology, 2019). Conservative estimates state 7% of the US population suffers from a Glueten Intollerance, or 32 million people.

Entreric Infections: A Worldwide Culprit

Milky Way Life Sciences is addressing significant medical conditions that are found around the world, such as Stunted Growth Syndrome (dwarfism). Dwarfism causes impaired cognition, increased risk of heart disease, stroke, Type 2 Diabetes, and premature death. In 2019 alone 21% of children under 5 in Asia, Africa, and Latin America suffered from Stunted Growth Syndrome, or 144 million children (World Health Organization). The cause of Stunted Growth Syndrome is intestinal infection - just one of the infections Milky Way Life Sciences is addressing.

Unmet Medical Need

There is no cure for Gluten Intolerance. Milky Way Life Sciences has developed a first-to-market treatment.

Large Population

7% of the US population, 23 million people, can’t eat gluten, driving an estimated gluten-free food market of $7.41 billion-dollars. (Gluten Free Food Market Report 2022-2026, The Business Research Company.)

Ambitious Goals

Milky Way Life Sciences is leveraging the benefits of colostrum to treat significant health needs worldwide.

Milky Way Life Sciences has positioned itself to solve significant medical conditions that span the world, helping under-served patients wherever they are.

R&D Pipeline

Experience, expertise, and vision. These assets set Milky Way Life Sciences apart. Its R&D pipeline is based on a core technology platform of colostrum.

platform_1